Evolus, Inc. (EOLS) is a biotech company that has gained FDA approval for its lead product Jeuveau, which is the only known Neurotoxin dedicated to the aesthetics or more specific treatment of glabellar lines. Ever since the commercial launch, everyone in the aesthetics treatment industry has been curious whether the company can take away a larger market share from Botox. The company has been successful so far to reach new accounts and drive revenue growth over the last couple of quarters, but the most recent coronavirus related crisis resulted in the complete loss